At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 197 enrolled
Drug / intervention
BMS-986036 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2B Randomized Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
In Brief
A Phase 2 clinical trial evaluating BMS-986036 and Placebo for Liver Fibrosis and 2 related conditions. Completed, enrolled 197 participants across 89 sites in 2 countries.
Detailed Summary
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartJun 2018
Primary CompletionSep 2020
Study CompletionAug 2021
TodayJul 2026
First PostedApr 3, 2018
Enrollment StartJun 19, 2018
Primary CompletionSep 14, 2020
Study CompletionAug 17, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.2 years ago
Interventions
BMS-986036drug
Specified dose on specified days.
Placeboother
Specified dose on specified days.